Vyleesi
Evidence Grade A — Regulatory approved. 87 published studies. 9 registered clinical trials.
Loading...
Bremelanotide (sold as Vyleesi) is an as-needed injectable treatment for low sexual desire in premenopausal women — specifically for a condition called HSDD (hypoactive sexual desire disorder) where persistently low desire causes personal distress. Unlike hormonal treatments, it works through the brain's melanocortin system to help activate the neural pathways involved in sexual desire. It was developed from the same family of research that produced the unregulated tanning peptides.
87 published studies: 62 human, 5 animal, 1 in-vitro, 47 reviews
Bremelanotide is marketed as Vyleesi (approved June 2019). It is indicated for premenopausal women with acquired, generalised HSDD. Administered as a self-injection using an autoinjector, with a maximum of one dose per 24 hours and no more than eight doses per month.
In clinical trials, approximately 25% of women reported meaningful improvement in sexual desire (compared to 17% on placebo). The most common side effects are nausea (40%), flushing, and headache — the nausea has been a significant barrier to uptake. Bremelanotide can cause transient blood pressure increases and skin darkening with repeated use. Commercial adoption has been limited by the injection requirement, modest efficacy over placebo, and the nausea profile.
Unlike treatments that work on blood flow or hormones, bremelanotide acts in the brain. It activates melanocortin-4 receptors in areas of the brain involved in sexual desire and arousal, modulating the dopamine pathways that underpin sexual motivation. This central mechanism is fundamentally different from medications like sildenafil (Viagra), which work peripherally on blood vessels. The melanocortin system's role in sexual function was actually discovered accidentally during tanning peptide research, when early clinical subjects reported unexpected effects on sexual arousal.
In two clinical trials, about 25% of women on bremelanotide reported a meaningful improvement in sexual desire, compared to 17% on placebo — a statistically significant but modest difference. Importantly, there was no significant increase in the number of satisfying sexual events, only in the desire and distress measures. Nausea is the most prominent side effect, reported by 40% of patients, and was the main reason people stopped using it. Real-world reception has been mixed. Some users report dramatic improvements, while others experience nausea severe enough to outweigh any benefit. The injection requirement (self-administered at least 45 minutes before anticipated activity), limited to eight doses per month, has also been a practical barrier. Other concerns include transient blood pressure increases and the possibility of permanent skin darkening with repeated use. Commercial uptake has been limited. Bremelanotide's origins as a derivative of Melanotan II connect it to the broader research peptide space, though it is the only product from that lineage with full regulatory approval.
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
FDA ORIG 1
FDA SUPPL 2
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
